Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XPH Guru Trades in

XPH Guru Trades in

Q4 2014

XPH Guru Trades in Q4 2014

Ken Fisher 3,425 sh (New)
» More
Q1 2015

XPH Guru Trades in Q1 2015

Ken Fisher Sold Out
» More

Ratios

vs
industry
vs
history
P/E(ttm) 25.58
XPH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 25.58 )
Ranked among companies with meaningful P/E(ttm) only.
XPH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 31.71
Current: 25.58
0
31.71
PE(NRI) 25.58
XPH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 25.58 )
Ranked among companies with meaningful PE(NRI) only.
XPH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 31.71
Current: 25.58
0
31.71
P/B 2.36
XPH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 2.36 )
Ranked among companies with meaningful P/B only.
XPH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.79
Current: 2.36
0
2.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.58
XPH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.58 )
Ranked among companies with meaningful Dividend Yield only.
XPH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.6
Current: 0.58
0
0.6
Yield on cost (5-Year) 0.58
XPH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.58 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XPH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.6
Current: 0.58
0
0.6

More Statistics

Short Percentage of Float0.00%
52-Week Range $36.67 - 52.03
Shares Outstanding (Mil)12,350,270.00
» More Articles for XPH

Headlines

Articles On GuruFocus.com
Agilent Technologies Raises Dividend 15% Dec 06 2016 
Can Zest Fresh Revolutionize an Industry? Dec 06 2016 
Microsoft’s Downside Dec 06 2016 
Barnes & Noble Education Reports Sales Slump Dec 06 2016 
Nihon Kagaku Sangyo Looks Undervalued Dec 06 2016 
Why Palo Alto Networks Is the Best Cybersecurity Play Dec 06 2016 
AbbVie, Johns Hopkins Unite for Cancer Research Dec 06 2016 
Is Under Armour a Safe Bet? Dec 06 2016 
Bullish on Occidental Petroleum as Oil Trends Higher Dec 06 2016 
HollyFrontier Benefits From Credit Suisse Upgrade Dec 06 2016 

More From Other Websites
Inside Merck’s Profitability after 3Q16 Dec 05 2016
Two Nano-Cap Pharma Stocks To Watch Right Now Dec 02 2016
5 Secret Santa ETFs & Stocks for Your Portfolio Dec 02 2016
Five ways to evaluate an Obamacare replacement plan Dec 01 2016
What to expect from HHS Secretary nominee and Obamacare opponent Tom Price Dec 01 2016
A Closer Look at Merck’s Valuation Compared to Peers Nov 30 2016
Where Else Have We Seen Mallinckrodt’s ‘Acquire to Invest’ Strategy? Nov 27 2016
What You Need to Know about Eli Lilly’s Cardiovascular Franchise Nov 23 2016
What Do the Analysts Recommend for Bristol-Myers Squibb’s Stock? Nov 22 2016
Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios Nov 17 2016
Biotech takes Trump presidency as a green light — and end to drug price worries Nov 16 2016
5 Reasons to Buy 5 Low P/E Biotech ETFs Nov 14 2016
Corbus Pharmaceuticals stock more than doubles after positive drug trial results Nov 14 2016
Healthcare: "A Better Buy Than A Sell" Nov 04 2016
Can Key Level Stop The Bleeding In Health Care Stocks? Oct 31 2016
Understanding the Growth Contributors in Pfizer’s 3Q16 Estimates Oct 31 2016
Januvia and Janumet: Merck’s Blockbuster Diabetes Products Oct 31 2016
Another Health Care Chart Looks Sick Oct 20 2016
Eli Lilly and Co.’s 3Q16 Estimates: Cardiovascular Franchise Oct 20 2016
BMY’s Drug Treatments That Go beyond Immuno-Oncology Oct 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK